[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366406-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366406-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","liquid-biopsy-and-epigenetic-signatures-in-aml-all-and-cns-tumors-diagnostic-and-monitoring-perspectives","Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors - Diagnostic and Monitoring Perspectives","","Clinicians need rapid, accurate cancer diagnoses that define tumor type, stage, and prognosis, while reducing reliance on repetitive invasive procedures such as biopsies and myelograms. Non-invasive monitoring is a promising route for tumor detection, screening, and prognostication. Evidence highlights epigenetics as a key regulator of stem cell fate, including proliferation, self-renewal, and malignant transformation. This supports analyzing the methylome, exosomes, and circulating RNA. Integrating liquid biopsy with epigenetic assays could enable fast, non-invasive diagnosis, real-time monitoring, and personalized treatment decisions for AML/ALL and CNS tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/liquid-biopsy-and-epigenetic-signatures-in-aml-all-and-cns-tumors-diagnostic-and-monitoring-perspectives/366406/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/liquid-biopsy-and-epigenetic-signatures-in-aml-all-and-cns-tumors-diagnostic-and-monitoring-perspectives/366406.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are non-invasive monitoring approaches important in AML, ALL, and CNS tumors?","Question",{"text":63,"@type":64},"They help reduce the need for repetitive invasive procedures such as biopsies and myelograms, lowering associated risks while supporting tumor detection, screening, and prognostication.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What epigenetic components does the review focus on for liquid biopsy-based diagnostics?",{"text":68,"@type":64},"It emphasizes epigenetic regulation through analysis of the methylome and circulating RNA, aiming to detect cellular transformation and support diagnostic and monitoring use cases.",{"name":70,"@type":61,"acceptedAnswer":71},"How could liquid biopsy combined with epigenetic analysis change tumor management?",{"text":72,"@type":64},"By enabling rapid, non-invasive diagnosis, real-time monitoring, and personalized treatment decisions, potentially improving differentiation among CNS tumor types and supporting detection and monitoring of acute myeloid/lymphoid leukemia.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366406,1790526808,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nLiquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives  \nAnne Aries 1, Bernard Drénou 1,2 and Rachid Lahlil 1, *  \nAcademic Editor: Albrecht Reichle  \nReceived: 12 June 2025  \nRevised: 30 July 2025  \nAccepted: 1 August 2025  \nPublished: 5 August 2025  \nCitation: Aries, A.; Drénou, B.; Lahlil, R. Liquid Biopsy and Epigenetic Signatures inAML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives. Int. J. Mol. Sci. 2025, 26, 7547. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26157547  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Institut de Recherche en Hématologie et Transplantation (IRHT), Hôpital du Hasenrain, 87 Avenue d’Altkirch,  \n68100 Mulhouse, France; [ariesa@ghrmsa.fr](ariesa@ghrmsa.fr) (A.A.); [drenoub@ghrmsa.fr](drenoub@ghrmsa.fr) (B.D.)  \n2 Laboratoire d’Hématologie, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Hôpital E. Muller, 20 Avenue de Dr. Laennec, 68100 Mulhouse, France  \n* Correspondence: [rachid.lahlil@ghrmsa.fr](rachid.lahlil@ghrmsa.fr)  \nAbstract  \nTo deliver the most effective cancer treatment, clinicians require rapid and accurate diagnoses that delineate tumor type, stage, and prognosis. Consequently, minimizing the need for repetitive and invasive procedures like biopsies and myelograms, along with their associated risks, is a critical challenge. Non-invasive monitoring offers a promising avenue for tumor detection, screening, and prognostication. While the identification of oncogenesand biomarkers from circulating tumor cells or tissue biopsies is currently standard practice for cancer diagnosis and classification, accumulating evidence underscores the significant role of epigenetics in regulating stem cell fate, including proliferation, self-renewal, and malignant transformation. This highlights the importance of analyzing the methylome, exosomes, and circulating RNA for detecting cellular transformation. The development of diagnostic assays that integrate liquid biopsies with epigenetic analysis holds immense potential for revolutionizing tumor management by enabling rapid, non-invasive diagnosis, real-time monitoring, and personalized treatment decisions. This review covers current studies exploring the use of epigenetic regulation, specifically the methylome and circulating RNA, as diagnostic tools derived from liquid biopsies. This approach shows promise in facilitating the differentiation between primary central nervous system lymphoma and other central nervous system tumors and may enable the detection and monitoring of acute myeloid/lymphoid leukemia. We also discuss the current limitations hindering the rapid clinical translation of these technologies.  \nKeywords: epigenetic; liquid biopsy; methylome; circulating RNA; leukemia; lymphoma; PCNSL; early diagnosis  \n1. Introduction  \nEpigenetic modifications during cancer initiation and progression provide significant biological insights. Cancer cells primarily achieve these epigenetic changes through DNA methylation, histone modifications, remodeling and repositioning of nucleosomes, and circulating RNA (e.g., microRNA) . The potential use of this knowledge in diagnosis and the design of more effective treatment strategies is currently a major focus in medical and scientific research. DNA methylation plays a fundamental role in cancer development and has emerged as a promising biomarker for various malignancies, including leukemia and brain tumors [1,2] . As a crucial epigenetic modification that regulates gene activity, it involves the addition of a methyl group to the cytosine base of DNA, specifically at sites  \nknown as CpG islands","cbCaisKp0ipi951d","https://ap.wps.com/l/cbCaisKp0ipi951d","pdf",1059705,25,"English","# Abstract\n# Introduction\n## Epigenetic modifications in cancer\n## DNA methylation as a biomarker\n## Circulating RNA and diagnostic potential\n# Limitations and clinical translation","[{\"question\":\"Why are non-invasive monitoring approaches important in AML, ALL, and CNS tumors?\",\"answer\":\"They help reduce the need for repetitive invasive procedures such as biopsies and myelograms, lowering associated risks while supporting tumor detection, screening, and prognostication.\"},{\"question\":\"What epigenetic components does the review focus on for liquid biopsy-based diagnostics?\",\"answer\":\"It emphasizes epigenetic regulation through analysis of the methylome and circulating RNA, aiming to detect cellular transformation and support diagnostic and monitoring use cases.\"},{\"question\":\"How could liquid biopsy combined with epigenetic analysis change tumor management?\",\"answer\":\"By enabling rapid, non-invasive diagnosis, real-time monitoring, and personalized treatment decisions, potentially improving differentiation among CNS tumor types and supporting detection and monitoring of acute myeloid/lymphoid leukemia.\"}]","Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors - Diagnostic and Monitoring Perspectives | PDF",1790165367,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e00a9f467f3c12582120c422fbf56bed.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/852e45562437c5dac2ff7c12ce2f317c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53ddc837ae5ac1c54a38b03ff69c4335.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b9eda6a9c51ed8b6b63be7015f9f7c1.webp",980,1385]